NASDAQ:CNTB

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

Retrieved on: 
Thursday, November 30, 2023

Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management."

Key Points: 
  • Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to announce the publication of its latest report, titled "Transformative Therapies for Pruritus Management."
  • This comprehensive report delves into the critical issue of pruritus, or chronic itch, and its impact on patients, particularly those suffering from Primary Biliary Cholangitis (PBC), an autoimmune liver disease.
  • Stonegate Healthcare Partners identifies leading programs aiming to reshape the landscape of pruritus treatment and significantly improve patients' quality of life.
  • Companies featured in the report include ConnectBiopharma (NASDAQ: CNTB), Ironwood Pharmaceuticals (NASDAQ: IRWD), MirumPharmaceuticals (NASDAQ: MIRM), and Tharimmune (NASDAQ: THAR).

Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms

Retrieved on: 
Saturday, March 18, 2023

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.

Key Points: 
  • Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16.
  • In the study “CBP-201, a next-generation IL-4Rα antibody, achieved all primary and secondary efficacy endpoints in the treatment of adults with moderate-to-severe atopic dermatitis (AD): A randomized, double-blind, pivotal trial in China (CBP-201-CN002),” researchers reported on results from Stage 1 of the pivotal China trial of CBP-201 in moderate-to-severe AD.
  • Patients on active therapy experienced rapid relief of symptoms, with a reduction in itch at Week 1 and significant improvement in all study endpoints by Week 4, which was sustained to Week 16.
  • “We are honored to have data from our two CBP-201 atopic dermatitis studies at the prestigious American Academy of Dermatology Annual Meeting, showing rapid and sustained relief,” said Zheng Wei, Ph.D., Co-founder and CEO of Connect Biopharma.

Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions

Retrieved on: 
Friday, March 17, 2023

This is the first time CBP-201 AD improvements have been broken down by body regions and symptom subtypes.

Key Points: 
  • This is the first time CBP-201 AD improvements have been broken down by body regions and symptom subtypes.
  • In the abstract entitled “Rapid and Sustained Improvements with CBP-201 Across All Body Regions: Treatment of Atopic Dermatitis in a Phase 2b, Randomized, Double-blind, Placebo-controlled Trial (CBP-201-WW001),” researchers reported that CBP-201 demonstrated rapid improvement in AD as early as Week 2 and sustained at Week 16 across four body regions: head and neck, trunk, upper limbs and lower limbs, compared to placebo.
  • In addition to overall AD improvement across all four body regions, researchers also observed improvement for each classification of AD symptoms (signs): erythema, induration/papulation, lichenification and excoriation, within each body region.
  • “CBP 201 also showed good AD reductions in the head and neck region, which is often more difficult to treat.

Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Monday, March 6, 2023

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that two abstracts from its CBP-201 clinical development program in atopic dermatitis (AD) have been accepted for presentation at the American Academy of Dermatology (AAD), March 17-21, 2023, in New Orleans, LA.

Key Points: 
  • Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that two abstracts from its CBP-201 clinical development program in atopic dermatitis (AD) have been accepted for presentation at the American Academy of Dermatology (AAD), March 17-21, 2023, in New Orleans, LA.
  • Specifically, data from the Phase 2b CBP-201 global trial in moderate-to-severe AD will be presented as an online e-poster with an oral presentation.
  • Data from stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe AD has been accepted as a late-breaking abstract for oral presentation.
  • “We look forward to sharing our AD data, which we believe will continue to demonstrate CBP-201 differentiation, at this prestigious conference.”